AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11165126
Drug: Mistletoe extract
RxNorm normalized name: MISTLETOE EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mistletoe extract treatment (ML-1 standardized mistletoe preparation)
Trial: 11165126
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no mistletoe treatment)
Trial: 7975966
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (3 mg vaginal tablet or 0.5 mg intracervical gel)
Trial: 2686737
Drug: Captopril (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (twice or three times daily)
Trial: 19404617
Drug: Aspirin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (300 mg daily for 7 days)
Trial: 19404617
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg acute and 300 mg sub-acute)
Trial: 16940077
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin-tazobactam 12 g/1.5 g administered continuously over 24 h
Trial: 16940077
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin-tazobactam 3 g/0.375 g administered over 30 min every 6 h for 4 to 14 days
Trial: 15620828
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin-tazobactam
Trial: 11939682
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin-tazobactam
Trial: 16940077
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion and intermittent infusion
Trial: 14676594
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet with oral placebo for 5 months
Trial: 14676594
Drug: Low-calorie diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calorie diet with oral vitamin E (400 mg/d x 2 months, 100 mg/d x 3 months)
Trial: 31356703
Drug: present‐centered therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: present‐centered therapy (PCT; 10 sessions delivered over 8 weeks)
Trial: 31356703
Drug: minimal contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: minimal contact control (MCC; weekly therapist phone check‐in for 4 weeks)
Trial: 25633475
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi (12 or 24 weeks, once or twice per week)
Trial: 25633475
Drug: Aerobic exercise
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerobic exercise (supervised, twice per week for 24 weeks)
Trial: 22647826
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (amoxicillin 1000 mg, clarithromycin 500 mg, metronidazole 500 mg, lansoprazole 30 mg twice daily for 5 days)
Trial: 22647826
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (amoxicillin 1000 mg, clarithromycin 500 mg, lansoprazole 30 mg twice daily for 7 days)
Trial: 28428322
Drug: Multiple Daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Daily Insulin Injections (MDI)
Trial: 15243929
Drug: Acellular pertussis
RxNorm normalized name: Acellular pertussis vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acellular pertussis vaccine (ACP)
Trial: 15243929
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ACP vaccine)
Trial: 11181931
Drug: Cocaine 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.2 mg/kg i.v.
Trial: 11181931
Drug: Cocaine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine 0.4 mg/kg i.v.
Trial: 11181931
Drug: Cocaine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocaine (both doses)
Trial: 2897558
Drug: Acetylcholine sweatspot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetylcholine sweatspot test (0.1 ml 1% acetylcholine administered intradermally)
Trial: 30185575
Drug: Unguided Internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unguided Internet-based cognitive behaviour therapy (ICBT)
Trial: 26522083
Drug: Azacitidine/chemotherapy (arm-A)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azacitidine/chemotherapy (arm-A)
Trial: 26522083
Drug: Chemotherapy (arm-B)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (arm-B)
Trial: 16186270
Drug: HIIP 2.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIP 2.6 mg
Trial: 16186270
Drug: HIIP 5.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIP 5.2 mg
Trial: 16186270
Drug: HIIP 7.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIIP 7.8 mg
Trial: 27885499
Drug: Doxazosin 8
RxNorm normalized name: doxazosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 8 mg
Trial: 9566806
Drug: Daily dosing
RxNorm normalized name: Osmolex 322 MG Daily Dosing Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dosing of buprenorphine (maintenance doses every 24 h)
Trial: 9566806
Drug: Alternate-day dosing
RxNorm normalized name: Alternaria alternata
DrugBank: Alternaria alternata (DB10424)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternate-day dosing of buprenorphine (double maintenance doses every 48 h with placebo on intervening days)
Trial: 8070504
Drug: Conventional formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional formulation of metoprolol (100 mg)
Trial: 8070504
Drug: Sustained‐release formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained‐release formulation of metoprolol (100 mg)
Trial: 3135786
Drug: Praziquantel (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (2 x 20 mg kg‐1)
Trial: 3135786
Drug: Oltipraz (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz (2 x 15 mg kg‐1)
Trial: 12693575
Drug: Mass chemotherapy
RxNorm normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mass chemotherapy
Trial: 28583342
Drug: Flibanserin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flibanserin (100 mg/d)
Trial: 21295494
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day for 30 days, then 10 mg/day for 60 days
Trial: 21295494
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day to 10 mg/day
Trial: 20606776
Drug: HESA-A (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HESA-A (25 mg/Kg twice a day orally for 4 weeks)
Trial: 20606776
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same method as treatment for 4 weeks)
Trial: 16696414
Drug: Oral ibuprofen
RxNorm normalized name: ibuprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibuprofen suspension (3 doses given 24 hours apart)
Trial: 15208824
Drug: Aprepitant (Emend)
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant (Emend) in combination with standard antiemetic agents
Trial: 30978265
Drug: Standard antiemetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard antiemetic therapy
Trial: 8143470
Drug: 37.5 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37.5 g/day of albumin until the circulating albumin concentration increased to > 3.0 g/dL (> 30 g/L)
Trial: 2646246
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied 2% glycopyrrolate lotion/cream
Trial: 31500854
Drug: Sevelamer 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer 0.8 g (low-dose)
Trial: 31500854
Drug: Sevelamer 2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sevelamer 2.4 g (high-dose)
Trial: 31500854
Drug: Sevelamer (high-dose)
DrugBank: Sevelamer (DB00658)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevelamer (high-dose) in highest baseline phosphate quartile group
Trial: 23539427
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of bisoprolol fumarate 5 mg and hydrochlorothiazide 6.25 mg
Trial: 19697824
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1 microg kg(‐1) over 10 min, followed by 0.2 microg kg(‐1) h(‐1) continuous infusion)
Trial: 16537185
Drug: Single epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single epirubicin (80 mg/40 mL of normal saline) administered into the bladder within 6 hours postoperation
Trial: 16537185
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Epirubicin consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Trial: 16537185
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg mitomycin C, consecutively, instillation every week for 6-8 weeks and then every one month for 10 months
Trial: 2487539
Drug: tiapamil 450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapamil 450 mg b.i.d.
Trial: 322529
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of vitamin C
Trial: 27056586
Drug: Reslizumab 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reslizumab 3.0 mg/kg
Trial: 25974287
Drug: Amitriptyline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (titrated to a median of 50 mg, interquartile range 25-50 mg)
Trial: 19234425
Drug: Acupuncture treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture treatment (10 sessions over 5 weeks)
Trial: 16317318
Drug: Visual-feedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual-feedback therapy (bimonthly sessions)
Trial: 12725603
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by omeprazole for 21 days
Trial: 12725603
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy with omeprazole, clarithromycin, and tinidazole for 7 days followed by placebo for 21 days
Trial: 8259721
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 200 mg daily and placebo
Trial: 8259721
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) and Methotrexate (MTX) 7.5 mg once a week
Trial: 3916621
Drug: Computer assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer assisted conventional insulin therapy
Trial: 12949925
Drug: Cognitive‐behavior therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behavior therapy
Trial: 11729513
Drug: TPN +
RxNorm normalized name: Total Parenteral Nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN + FDP (1 g/kg daily for dogs; 5 g, two times a day for patients)
Trial: 31079530
Drug: Sodium reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium reduction (9 slow sodium tablets daily for 6 weeks)
Trial: 31079530
Drug: Placebo (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (placebo tablets daily for 6 weeks)
Trial: 26387142
Drug: Trastuzumab/chemotherapy (from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab/chemotherapy (from NOAH trial)
Trial: 26387142
Drug: Chemotherapy only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy only (from NOAH trial)
Trial: 21673612
Drug: Plain polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain polysaccharide vaccine (MenC-PS group, n=150)
Trial: 21673612
Drug: Glycoconjugate vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycoconjugate vaccine (MenC-CRM group, n=95)
Trial: 18325740
Drug: Galantamine (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (32 mg/day)
Trial: 12628548
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GR-1 and L. fermentum RC-14
Trial: 23301548
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (TDF) or emtricitabine (FTC)/TDF therapy
Trial: 23301548
Drug: TDF or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDF or FTC/TDF therapy
Trial: 21973194
Drug: 1064-nm Q-switched
RxNorm normalized name: Q
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1064-nm Q-switched neodymium-doped yttrium-aluminium-garnet laser monotherapy
Trial: 15349912
Drug: Telbivudine 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine 800 mg/d
Trial: 15349912
Drug: Telbivudine (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine (various doses: 25, 50, 100, 200, 400, and 800 mg/d)
Trial: 15349912
Drug: Telbivudine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telbivudine (400 mg/d or more)
Trial: 8839087
Drug: Metoclopramide 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 0.25 mg.kg-1 intravenously (two doses)
Trial: 8839087
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg.kg-1 intravenously (two doses)
Trial: 1495854
Drug: High-frequency jet
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-frequency jet ventilation (HFJV) with continued surfactant therapy
Trial: 6379678
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg indoprofen 4-times daily
Trial: 6379678
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg indomethacin 4-times daily
Trial: 18454224
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate 150 mg twice daily
Trial: 18454224
Drug: Dapsone 50
RxNorm normalized name: dapsone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone 50 mg twice daily
Trial: 18454224
Drug: Glucose 250
RxNorm normalized name: glucose 250 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 250 mg as placebo
Trial: 18425652
Drug: Dietary fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary fat restriction (22-26 g/day)
Trial: 1753937
Drug: Local and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local and systemic treatment with salcatonin
Trial: 17580516
Drug: Colchicine as
RxNorm normalized name: Colchicine
DrugBank: Colchicine (DB01394)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colchicine as adjunct to conventional treatment
Trial: 16145640
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg/kg added to 40 ml prilocaine 1.5%
Trial: 16145640
Drug: Clonidine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 1.5 microg/kg added to 40 ml prilocaine 1.5%
Trial: 16145640
Drug: Prilocaine 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prilocaine 1.5% without additional medication (Control)
Trial: 11835111
Drug: Sodium profile
RxNorm normalized name: PROFIMER SODIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium profile (decreasing sodium concentration from 145 to 133 mmol/L)
Trial: 11835111
Drug: Constant sodium
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant sodium concentration (138 mmol/L)
Trial: 31626156
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy + VR (15 minutes twice daily for 10 days)
Trial: 28629351
Drug: HRQOL assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HRQOL assessment considered important in daily work
Trial: 19704066
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg/mo (plus 500 mg on day 14 of month 1)
Trial: 16009955
Drug: Anastrozole 1
RxNorm normalized name: anastrozole 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anastrozole 1 mg/d
Trial: 17273013
Drug: Lavender essential
RxNorm normalized name: Nature's Truth Lavender Essential Oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lavender essential oil for inhalation
Trial: 17273013
Drug: Inert oil
RxNorm normalized name: inert ingredients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert oil (placebo) for inhalation
Trial: 12388962
Drug: Extra-amniotic saline
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extra-amniotic saline solution infusion
Trial: 8265095
Drug: 32 mg
RxNorm normalized name: caffeine 32 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 32 mg ondansetron
Trial: 19395466
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg granisetron
Trial: 3663434
Drug: Meptazinol 20
RxNorm normalized name: meptazinol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 20 mg
Trial: 3663434
Drug: Meptazinol 30
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 30 mg
Trial: 3663434
Drug: Meptazinol 48
RxNorm normalized name: meptazinol
DrugBank: Meptazinol (DB13478)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meptazinol 48 mg
Trial: 3663434
Drug: Pethidine 20
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine 20 mg
Trial: 29652755
Drug: Comprehensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive treatment and rehabilitation program including preop chemotherapy, surgery, postop rehabilitation, and mesodiencephalic modulation (MDM) sessions after each invasive intervention.
Trial: 25485879
Drug: Intraoperative dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative dexmedetomidine (1 μg kg(‐1) loading dose followed by 0.5 μg kg(‐1) h(‐1) continuous infusion)
Trial: 22922682
Drug: Ticagrelor (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (loading dose 270 mg; 90 mg twice daily for 7 days) plus atorvastatin (80 mg on day 5)
Trial: 22922682
Drug: Ticagrelor (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (loading dose 270 mg; 180 mg twice daily for 7 days) plus simvastatin (80 mg on day 5)
Trial: 22922682
Drug: Ticagrelor with
RxNorm normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ticagrelor with atorvastatin metabolites
Trial: 22922682
Drug: Ticagrelor (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor (single dose)
Trial: 22029963
Drug: MTRX1011A at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTRX1011A at 1.5 mg/kg subcutaneously (s.c.) weekly
Trial: 22029963
Drug: MTRX1011A at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTRX1011A at 3.5 mg/kg s.c. weekly
Trial: 22029963
Drug: MTRX1011A at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTRX1011A at 5 mg/kg intravenously (i.v.) weekly
Trial: 22029963
Drug: MTRX1011A (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTRX1011A (various doses)
Trial: 17026510
Drug: Repeated professional
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated professional tooth cleaning combined with oral hygiene instruction
Trial: 17026510
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene instruction only (Control)
Trial: 14629059
Drug: Ropivacaine (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine (higher dose)
Trial: 10930965
Drug: Enzyme-inducing antiepileptic
RxNorm normalized name: lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enzyme-inducing antiepileptic drugs without valproate
Trial: 2504972
Drug: Mifurol (6-12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifurol (6-12 mg/kg/day) + MMC (0.2 mg/kg x 2)